


Lymphoma

A NICE pathway brings together all NICE guidance, quality standards and materials to support implementation on a specific topic area. The pathways are interactive and designed to be used online. This pdf version gives you a single pathway diagram and uses numbering to link the boxes in the diagram to the associated recommendations.

To view the online version of this pathway visit:

<http://pathways.nice.org.uk/pathways/blood-and-bone-marrow-cancers>

Pathway last updated: 16 December 2014
Copyright © NICE 2014. All rights reserved



1 Person with lymphoma

No additional information

2 Non-Hodgkin's lymphoma

NICE is producing a clinical guideline on [non-Hodgkin's lymphoma: diagnosis and management of non-Hodgkin's lymphoma](#), which is publishing in December 2015.

The appraisal of [idelalisib for treating refractory indolent non-Hodgkin's lymphoma](#) was terminated because no evidence submission was received from Gilead Sciences. Therefore NICE is **unable to make a recommendation** about the use in the NHS of idelalisib for treating refractory indolent non-Hodgkin's lymphoma.

The appraisal of [bendamustine for the treatment of indolent \(low grade\) non-Hodgkin's lymphoma that is refractory to rituximab](#) was terminated because no evidence submission was received from the manufacturer or sponsor of the technology. Therefore NICE is **unable to make a recommendation** about the use in the NHS of bendamustine for treating indolent (low grade) non-Hodgkin's lymphoma that is refractory to rituximab.

3 First-line and maintenance treatment and induction of remission (rituximab)

First line treatment for non-Hodgkin's lymphoma

Rituximab is recommended for use in combination with a regimen of cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) for the first-line treatment of people with CD20-positive diffuse large-B-cell lymphoma at clinical stage II, III or IV (see section 2.3 in [NICE technology appraisal guidance 65](#)). Rituximab is not recommended for use when CHOP is contraindicated.

The clinical and cost effectiveness of rituximab in patients with localised disease (Stage I, see Section 2.3 in [NICE technology appraisal guidance 65](#)) has not been established. It is recommended that rituximab be used in these circumstances only as part of ongoing or new clinical studies.

A specialist in the treatment of lymphomas should supervise the use of rituximab in combination with CHOP for the treatment of diffuse large-B-cell lymphoma.

These recommendations are from [rituximab for aggressive non-Hodgkin's lymphoma](#) NICE technology appraisal guidance 65.

NICE has written (information for the public explaining its guidance on [first-line rituximab for aggressive non-Hodgkin's lymphoma](#)).

First-line treatment for stage III or IV follicular non-Hodgkin's lymphoma

Rituximab, in combination with:

- cyclophosphamide, vincristine and prednisolone (CVP)
- cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP)
- mitoxantrone, chlorambucil and prednisolone (MCP)
- cyclophosphamide, doxorubicin, etoposide, prednisolone and interferon- α (CHVPI) or
- chlorambucil

is recommended as an option for the treatment of symptomatic stage III and IV follicular lymphoma in previously untreated people.

These recommendations are from [rituximab for the first-line treatment of stage III-IV follicular lymphoma: \(review of NICE technology appraisal guidance 110\)](#) NICE technology appraisal guidance 243.

NICE has written information for the public explaining its guidance on [first-line rituximab for stage III-IV follicular lymphoma](#).

Maintenance treatment for follicular non-Hodgkin's lymphoma

Rituximab maintenance therapy is recommended as an option for the treatment of people with follicular non-Hodgkin's lymphoma that has responded to first-line induction therapy with rituximab in combination with chemotherapy.

This recommendation is from [rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma](#) NICE technology appraisal guidance 226.

NICE has written information for the public explaining its guidance on [first-line rituximab for maintenance treatment of follicular non-Hodgkin's lymphoma](#).

Induction of remission for relapsed/refractory stage III or IV follicular non-Hodgkin's lymphoma

Rituximab, within its marketing authorisation, in combination with chemotherapy, is recommended as an option for the induction of remission in people with relapsed stage III or IV follicular non-Hodgkin's lymphoma.

Rituximab monotherapy as maintenance therapy, within its marketing authorisation, is recommended as an option for the treatment of people with relapsed stage III or IV follicular non-Hodgkin's lymphoma in remission induced with chemotherapy with or without rituximab.

Rituximab monotherapy, within its marketing authorisation, is recommended as an option for the treatment of people with relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma, when all alternative treatment options have been exhausted (that is, if there is resistance to or intolerance of chemotherapy).

This recommendations are from [rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma: Review of technology appraisal guidance 37](#) NICE technology appraisal guidance 137.

NICE has written information for the public explaining its guidance on [rituximab for relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma](#).

Resources

The following implementation tools are relevant to this part of the pathway.

[Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma: Review of technology appraisal guidance 37: audit support](#)

[Rituximab for the first-line treatment of stage III-IV follicular lymphoma: \(review of NICE technology appraisal guidance 110\): costing statement](#)

[Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma: costing template](#)

[Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma: Review of technology appraisal guidance 37: costing template](#)

4 Multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma (pixantrone)

Pixantrone monotherapy is recommended as an option for treating adults with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma only if:

- the person has previously been treated with rituximab and
- the person is receiving third- or fourth-line treatment and
- the manufacturer provides pixantrone with the discount agreed in the patient access scheme.

People currently receiving treatment initiated within the NHS with pixantrone monotherapy that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

These recommendations are from [pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma](#) NICE technology appraisal guidance 306.

NICE has written information for the public explaining its guidance on [pixantrone](#).

Resources

The following implementation tools are relevant to this part of the pathway.

[Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma: costing statement](#)

5 Mantle cell lymphoma

The appraisal of [Temsirrolimus for the treatment of relapsed or refractory mantle cell lymphoma](#) NICE technology appraisal 207 was terminated because no evidence submission was received from the manufacturer or sponsor of the technology. Therefore NICE is **unable to make a recommendation** about the use in the NHS of temsirrolimus for treating relapsed or refractory mantle cell lymphoma.

Sources

[Idelalisib for treating refractory indolent non-Hodgkin's lymphoma \(terminated appraisal\) \(2014\) NICE technology appraisal 328](#)

[Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma \(2014\) NICE technology appraisal guidance 306](#)

[Rituximab for the first-line treatment of stage III-IV follicular lymphoma: \(review of NICE technology appraisal guidance 110\) \(2012\) NICE technology appraisal guidance 243](#)

[Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma \(2011\) NICE technology appraisal guidance 226](#)

[Temsirolimus for the treatment of relapsed or refractory mantle cell lymphoma \(terminated appraisal\) \(2010\) NICE technology appraisal 207](#)

[Bendamustine for the treatment of indolent \(low grade\) non-Hodgkin's lymphoma that is refractory to rituximab \(terminated appraisal\) \(2010\) NICE technology appraisal 206](#)

[Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma: Review of technology appraisal guidance 37 \(2008\) NICE technology appraisal guidance 137](#)

[Rituximab for aggressive non-Hodgkin's lymphoma \(2003\) NICE technology appraisal guidance 65](#)

Your responsibility

The guidance in this pathway represents the view of NICE, which was arrived at after careful consideration of the evidence available. Those working in the NHS, local authorities, the wider public, voluntary and community sectors and the private sector should take it into account when carrying out their professional, managerial or voluntary duties. Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

Copyright

Copyright © National Institute for Health and Care Excellence 2014. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

Contact NICE

National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

www.nice.org.uk

nice@nice.org.uk

0845 003 7781